CAS NO: | 341028-37-3 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
200mg | 电议 |
500mg | 电议 |
1 g | 电议 |
生物活性 | Alagebrium chloride (ALT711) is anadvanced glycation end product(AGE) inhibitor. | ||||||||||||||||
IC50& Target | AGE[1] | ||||||||||||||||
体外研究 (In Vitro) | Alagebrium chloride is anadvanced glycation end product(AGE) inhibitor. Endothelial cell (EC) proliferation is increased for all groups receiving Alagebrium (ALT-711), particularly when seeded on matrix from the AAo of obese (ZO) and diabetic (ZD) rats[2]. | ||||||||||||||||
体内研究 (In Vivo) | Blood pressure is not affected by treatment with Alagebrium. In diabetic RAGE apoE double-KO mice, treatment with Alagebrium is associated with a modest reduction in renal mass and reduces hyperfiltration compare with nontreated mice. Treatment with Alagebrium in diabetic RAGE apoE double-KO mice is associated with a further reduction in glomerular collagen IV levels, approaching levels observed in control mice[1]. Body weight, heart rate (HR), and mean blood pressure (BP) are similar in Zucker lean (ZL), obese (ZO), and diabetic (ZD) groups in the absence or presence of Alagebrium (ALT-711). Alagebrium increases blood flow (BF) in ZO rats but reduces distal vascular resistance in ZD rats. A decrease in neointimal hyperplasia (NH) intrastrut thickness as a function of local radius is found in all groups with Alagebrium treatment. A significant increase in TGF-β expression is also found in the AAo of ZL rats treated with Alagebrium[2]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 267.77 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C13H14ClNOS | ||||||||||||||||
CAS 号 | 341028-37-3 | ||||||||||||||||
中文名称 | 阿拉氯胺 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: H2O : 50 mg/mL(186.73 mM;Need ultrasonic) DMSO : ≥ 25 mg/mL(93.36 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*以上所有助溶剂都可在本网站选购。 |